{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:45:02Z","timestamp":1791953102890,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Unplanned hospitalizations during systemic anticancer therapy remain a major clinical challenge. This study aimed to investigate the causes of unplanned hospitalizations associated with systemic anticancer therapy-related adverse events and to assess their potential preventability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective analysis of unplanned hospitalizations due to adverse events related to systemic anticancer therapy between March 1, 2023, and March 31, 2024. The type, severity, and treatment of adverse events leading to unplanned hospitalization were reviewed. The preventability of these hospitalizations was assessed by a multidisciplinary team (pharmacists, physicians, and nurses) based on domestic and international guidelines and previous reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 161 cases of unplanned hospitalizations due to systemic anticancer therapy-related adverse events were identified. Among these, 30 cases (18.6%) were considered potentially preventable. The types of potentially preventable interventions included optimization of supportive care, such as G-CSF prophylaxis, antimicrobial prophylaxis, and antiemetic optimization (15 cases); optimization of anticancer therapy, including dose reduction\/modification (6 cases); early detection and management, including enhanced monitoring and patient education (6 cases); and preventive measures before anticancer therapy, including varicella-zoster virus vaccination (5 cases).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 20% of unplanned hospitalizations related to systemic anticancer therapy were potentially preventable. Optimization of supportive care and enhancement of medical care systems could reduce unplanned hospitalizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11351-0","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:42:59Z","timestamp":1791927779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potentially preventable unplanned hospitalizations due to adverse events in patients receiving systemic anticancer therapy: a retrospective single-center study"],"prefix":"10.1007","volume":"34","author":[{"given":"Momoka","family":"Endo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"1","key":"11351_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"11351_CR2","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.18632\/aging.204839","volume":"15","author":"DT Michaeli","year":"2023","unstructured":"Michaeli DT, Michaeli JC, Michaeli T (2023) Advances in cancer therapy: clinical benefit of new cancer drugs. Aging (Albany NY) 15(12):5232\u20135234. https:\/\/doi.org\/10.18632\/aging.204839","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"11351_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"11351_CR4","doi-asserted-by":"publisher","first-page":"e2339116","DOI":"10.1001\/jamanetworkopen.2023.39116","volume":"6","author":"JC Baltussen","year":"2023","unstructured":"Baltussen JC, de Glas NA, van Holstein Y et al (2023) Chemotherapy-related toxic effects and quality of life and physical functioning in older patients. JAMA Netw Open 6(10):e2339116. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39116","journal-title":"JAMA Netw Open"},{"issue":"1","key":"11351_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.21037\/jtd-23-1532","volume":"16","author":"K Takada","year":"2024","unstructured":"Takada K, Takamori S, Mizuki F et al (2024) Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials. J Thorac Dis 16(1):430\u2013438. https:\/\/doi.org\/10.21037\/jtd-23-1532","journal-title":"J Thorac Dis"},{"issue":"5","key":"11351_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JOP.17.00081","volume":"14","author":"NR Handley","year":"2018","unstructured":"Handley NR, Schuchter LM, Bekelman JE (2018) Best practices for reducing unplanned acute care for patients with cancer. J Oncol Pract 14(5):306\u2013313. https:\/\/doi.org\/10.1200\/JOP.17.00081","journal-title":"J Oncol Pract"},{"key":"11351_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00147","volume":"3","author":"GA Brooks","year":"2019","unstructured":"Brooks GA, Uno H, Aiello Bowles EJ et al (2019) Hospitalization risk during chemotherapy for advanced cancer: development and validation of risk stratification models using real-world data. JCO Clin Cancer Inform 3:1\u201310. https:\/\/doi.org\/10.1200\/CCI.18.00147","journal-title":"JCO Clin Cancer Inform"},{"issue":"10","key":"11351_CR8","doi-asserted-by":"publisher","first-page":"e1912823","DOI":"10.1001\/jamanetworkopen.2019.12823","volume":"2","author":"RC Grant","year":"2019","unstructured":"Grant RC, Moineddin R, Yao Z et al (2019) Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer. JAMA Netw Open 2(10):e1912823. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12823","journal-title":"JAMA Netw Open"},{"key":"11351_CR9","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1200\/OP.20.00681","volume":"17","author":"HD Klepin","year":"2021","unstructured":"Klepin HD, Sun CL, Smith DD et al (2021) Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy. JCO Oncol Pract 17:e740\u2013e752. https:\/\/doi.org\/10.1200\/OP.20.00681","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"11351_CR10","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1002\/cncr.32896","volume":"126","author":"R Gidwani-Marszowski","year":"2020","unstructured":"Gidwani-Marszowski R, Faricy-Anderson K, Asch SM et al (2020) Potentially preventable hospitalizations after chemotherapy: differences across medicare and the veterans health administration. Cancer 126(14):3297\u20133302. https:\/\/doi.org\/10.1002\/cncr.32896","journal-title":"Cancer"},{"issue":"2","key":"11351_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.critrevonc.2014.12.011","volume":"94","author":"XJ Wang","year":"2015","unstructured":"Wang XJ, Lopez SE, Chan A (2015) Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Crit Rev Oncol Hematol 94(2):201\u2013212. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.12.011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"28","key":"11351_CR12","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"2","key":"11351_CR13","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"issue":"7","key":"11351_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29(7):873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"issue":"30","key":"11351_CR15","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36(30):3043\u20133054. https:\/\/doi.org\/10.1200\/JCO.18.00374","journal-title":"J Clin Oncol"},{"issue":"5","key":"11351_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ecc.12246","volume":"24","author":"R Wagland","year":"2015","unstructured":"Wagland R, Richardson A, Armes J et al (2015) Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review. Eur J Cancer Care (Engl) 24(5):605\u2013617. https:\/\/doi.org\/10.1111\/ecc.12246","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"11351_CR17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.2013.52.4330","volume":"32","author":"GA Brooks","year":"2014","unstructured":"Brooks GA, Abrams TA, Meyerhardt JA et al (2014) Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol 32(6):496\u2013503. https:\/\/doi.org\/10.1200\/JCO.2013.52.4330","journal-title":"J Clin Oncol"},{"issue":"1","key":"11351_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1186\/s12885-025-14513-1","volume":"25","author":"TE Cetin","year":"2025","unstructured":"Cetin TE, Sutcuoglu O, Akdogan O et al (2025) Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis. BMC Cancer 25(1):1111. https:\/\/doi.org\/10.1186\/s12885-025-14513-1","journal-title":"BMC Cancer"},{"key":"11351_CR19","doi-asserted-by":"publisher","first-page":"12301","DOI":"10.2147\/CMAR.S277924","volume":"12","author":"E Tashkandi","year":"2020","unstructured":"Tashkandi E, Basulaiman B, Alghareeb W et al (2020) Thirty-day mortality after curative and palliative anti-cancer treatment: data interpretation and lessons for clinical implementation. Cancer Manag Res 12:12301\u201312308. https:\/\/doi.org\/10.2147\/CMAR.S277924","journal-title":"Cancer Manag Res"},{"issue":"1","key":"11351_CR20","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JOP.18.00254","volume":"15","author":"RL Whitney","year":"2019","unstructured":"Whitney RL, Bell JF, Tancredi DJ et al (2019) Unplanned hospitalization among individuals with cancer in the year after diagnosis. J Oncol Pract 15(1):e20\u2013e29. https:\/\/doi.org\/10.1200\/JOP.18.00254","journal-title":"J Oncol Pract"},{"issue":"14","key":"11351_CR21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM et al (2024) Vaccination of adults with cancer: ASCO Guideline. J Clin Oncol 42(14):1699\u20131721. https:\/\/doi.org\/10.1200\/JCO.24.00032","journal-title":"J Clin Oncol"},{"key":"11351_CR22","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.5888\/pcd21.240138","volume":"21","author":"DJ Bilicki","year":"2024","unstructured":"Bilicki DJ, Reeves MJ (2024) Outpatient follow-up visits to reduce 30-day all-cause readmissions for heart failure, COPD, myocardial infarction, and stroke: a systematic review and meta-analysis. Prev Chronic Dis 21:E74. https:\/\/doi.org\/10.5888\/pcd21.240138","journal-title":"Prev Chronic Dis"},{"issue":"11","key":"11351_CR23","doi-asserted-by":"publisher","first-page":"e2541272","DOI":"10.1001\/jamanetworkopen.2025.41272","volume":"8","author":"I Balasubramanian","year":"2025","unstructured":"Balasubramanian I, Andres EB, Malhotra C (2025) Outpatient Follow-Up and 30-Day Readmissions: A Systematic Review and Meta-Analysis. JAMA Netw Open 8(11):e2541272. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.41272","journal-title":"JAMA Netw Open"},{"issue":"12","key":"11351_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00520-025-10042-6","volume":"33","author":"N Shibata","year":"2025","unstructured":"Shibata N, Kuwazawa H, Yasukawa T et al (2025) The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study. Support Care Cancer 33(12):1115. https:\/\/doi.org\/10.1007\/s00520-025-10042-6","journal-title":"Support Care Cancer"},{"issue":"1","key":"11351_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01845-8","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 japan society of clinical oncology clinical practice guidelines for antiemesis. Int J Clin Oncol 26(1):1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01845-8","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"11351_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.annonc.2025.10.017","volume":"37","author":"A Molassiotis","year":"2026","unstructured":"Molassiotis A, Jordan K, Karthaus M et al (2026) Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. Ann Oncol 37(2):260\u2013270. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.017","journal-title":"Ann Oncol"},{"issue":"4","key":"11351_CR27","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56\u2013e93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"issue":"9","key":"11351_CR28","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14(9):2590\u20132611. https:\/\/doi.org\/10.1200\/JCO.1996.14.9.2590","journal-title":"J Clin Oncol"},{"issue":"4","key":"11351_CR29","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA et al (2019) Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 20(4):e200\u2013e207. https:\/\/doi.org\/10.1016\/S1470-2045(19)30145-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"11351_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1078155216634180","volume":"23","author":"A Crespo","year":"2017","unstructured":"Crespo A, Tyszka M (2017) Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract 23(4):243\u2013248. https:\/\/doi.org\/10.1177\/1078155216634180","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"11351_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13187-015-0801-8","volume":"31","author":"ZA \u015eahin","year":"2016","unstructured":"\u015eahin ZA, Erg\u00fcney S (2016) Effect on symptom management education receiving patients of chemotherapy. J Cancer Educ 31(1):101\u2013107. https:\/\/doi.org\/10.1007\/s13187-015-0801-8","journal-title":"J Cancer Educ"},{"issue":"9","key":"11351_CR32","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30469-4","volume":"19","author":"KM Mullane","year":"2019","unstructured":"Mullane KM, Morrison VA, Camacho LH et al (2019) Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis 19(9):1001\u20131012. https:\/\/doi.org\/10.1016\/S1473-3099(19)30469-4","journal-title":"Lancet Infect Dis"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11351-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:49:11Z","timestamp":1791949751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11351-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11351"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11351-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1094"}}